Duchenne Muscular Dystrophy Global Clinical Trials Review, H2, 2017

  • ID: 4382270
  • Clinical Trials
  • Region: Global
  • 166 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • Akashi Therapeutics Inc
  • Catabasis Pharmaceut
  • CureDuchenne
  • GlaxoSmithKline Plc
  • Prosensa Holding B.V.
  • PTC Therapeutics Inc
  • MORE
Duchenne Muscular Dystrophy Global Clinical Trials Review, H2, 2017

Summary

The clinical trial report, “Duchenne Muscular Dystrophy Global Clinical Trials Review, H2, 2017" provides an overview of Duchenne Muscular Dystrophy clinical trials scenario. This report provides top line data relating to the clinical trials on Duchenne Muscular Dystrophy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using the author’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Akashi Therapeutics Inc
  • Catabasis Pharmaceut
  • CureDuchenne
  • GlaxoSmithKline Plc
  • Prosensa Holding B.V.
  • PTC Therapeutics Inc
  • MORE
Report Guidance
Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Countries Contributing to Clinical Trials in Middle East and Africa
Top Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Duchenne Muscular Dystrophy Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Duchenne Muscular Dystrophy
Jul 18, 2017: PTC Therapeutics Announces Publication of Data from ACT DMD in The Lancet
Jun 26, 2017: Antisense Therapeutics to Enter Clinical Development in Duchenne Muscular Dystrophy
Jun 23, 2017: Catabasis Pharmaceuticals to Present Results from the MoveDMD Trial of Edasalonexent at the 2017 PPMD Annual Connect Conference
Jun 22, 2017: Summit Presents Data From Phase 1 Clinical Programme of Ezutromid at the European Paediatric Neurology Society Congress
Jun 22, 2017: New Analyses of Translarna (ataluren) Data from ACT DMD Presented at the 12th Annual European Pediatric Neurology Society Congress
Jun 14, 2017: CureDuchenne to Host Webinar with Santhera Pharmaceuticals on SIDEROS Trial
May 30, 2017: Pfizer Completes Enrollment of Phase 2 Study of Domagrozumab (PF- 06252616) in Duchenne Muscular Dystrophy
May 23, 2017: New Analysis of ACT DMD Placebo Data on Corticosteroids Presented at International Society for Pharmacoeconomics and Outcomes Research 22nd Annual International Meeting
May 16, 2017: Santhera to Present Data and Host Symposium on Pulmonary Function in Duchenne Muscular Dystrophy at the American Thoracic Society 113th Annual Conference
May 15, 2017: Summit Completes Enrolment of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients with DMD
May 11, 2017: New Preclinical Data Support SGT-001 As A Novel Treatment Approach For Duchenne Muscular Dystrophy
May 03, 2017: GTx Announces Results from Preclinical Studies of SARMs in Duchenne Muscular Dystrophy Models Published in Human Molecular Genetics
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About
Contact
Source

List of Tables
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Region, 2017*
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Europe, Top Five Countries, 2017*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, North America, Top Countries, 2017*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Central and South America, Top Countries, 2017*
Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, G7 Countries (%), 2017*
Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, E7 Countries (%), 2017*
Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Phase, 2017*
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Phase 2017*
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Trial Status, 2017*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, by End Point Status, 2017*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
Duchenne Muscular Dystrophy Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*

List of Figures
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Region (%), 2017*
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, North America, Top Countries (%), 2017*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2017*
Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, G7 Countries (%), 2017*
Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, E7 Countries (%), 2017*
Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Phase (%), 2017*
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Phase, 2017*
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Trial Status, 2017*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, by End Point Status, 2017*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
Duchenne Muscular Dystrophy Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
Methodology
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • BioMarin Pharmaceutical Inc
  • PTC Therapeutics Inc
  • Sarepta Therapeutics Inc
  • Marathon Pharmaceuticals LLC
  • GlaxoSmithKline Plc
  • Summit Therapeutics Plc
  • Akashi Therapeutics Inc
  • Prosensa Holding B.V.
  • CureDuchenne
  • Catabasis Pharmaceut
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll